Rash

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

Retrieved on: 
Donnerstag, Mai 9, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, FDA, Society, Cancer, Skin, Safety, Research, Joint, Research and development, IRB, Cell, Administration, IND, LEKTI, ASCO, Ichthyosis, Patent, Patient, Gene, Bayer, Prevalence, Rash, Quarter, EGFR, G&A, Netherton syndrome, BTK, Chemotherapy, Pharmaceutical industry

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended March 31, 2024, and provided a business update.

Key Points: 
  • Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended March 31, 2024, and provided a business update.
  • Moreover, preclinical evidence suggests that ATR-12 can markedly reduce IL-36g, a pro-inflammatory cytokine implicated in Netherton syndrome, further validating the potential of our approach.
  • Net Loss was $2.9 million for the quarter ended March 31, 2024, compared to $2.5 million for the comparable period in 2023.
  • Cash and cash equivalents: As of March 31, 2024, the Company had cash and cash equivalents of $3.0 million.

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

Retrieved on: 
Mittwoch, Mai 8, 2024
CD3, Patient, Arthralgia, EDT, HNSCC, CRS, Safety, Pancreatic cancer, Itch, RECIST, PDT, CRC, Trial of the century, Tumor microenvironment, Webcast, Tenosynovitis, Therapy, Vomiting, Arthritis, Rash, Head, Neoplasm, EGFR, Cancer, NSCLC, SAN, Amgen, Lung cancer, Pharmaceutical industry

“These data build on more than a decade of innovation at CytomX, and, we believe, open broad new possibilities for T-cell engagers across many targets and cancer types.

Key Points: 
  • “These data build on more than a decade of innovation at CytomX, and, we believe, open broad new possibilities for T-cell engagers across many targets and cancer types.
  • CX-904 Phase 1a dose escalation and optimization continue, with future enrollment focused on determining a recommended Phase 2 dose, or doses.
  • The Company expects to provide an additional Phase 1a dose escalation update by the end of 2024.
  • These additional data will inform discussions with CytomX partner, Amgen, towards initiation of Phase 1b expansion cohorts in specific EGFR positive tumor types.

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Mittwoch, Mai 8, 2024
MSD, Investment, Pancreatic cancer, Research, TCE, CRC, Trial of the century, Webcast, Drug discovery, EGFR, Bladder cancer, Cancer, CRS, Cytokine, Tumor microenvironment, ADC, Vomiting, Therapeutic index, Kidney, Bristol Myers Squibb, Therapy, Biotechnology, Spacecraft, SAN, Arthralgia, Safety, Pembrolizumab, RECIST, Arthritis, GLP, Melanoma, BMS, Toxicology, CD3, EDT, Itch, Merck & Co., PDT, Camptothecin, Patient, Rash, Head, Epithelial cell adhesion molecule, Amgen, Pharmaceutical industry

Initial data anticipated in 2025 -

Key Points: 
  • Initial data anticipated in 2025 -
    - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT -
    SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today reported first quarter 2024 financial results and provided a business update.
  • The Company expects to provide an additional Phase 1a dose escalation update by the end of 2024.
  • The cash balance as of March 31, 2024, does not include the $10.0 million of Astellas milestone achievements earned in the first quarter of 2024.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Dienstag, Mai 7, 2024
FDA, Carcinoma, CMO, Peripheral neuropathy, Investment, Safety, Pharmacokinetics, Rash, MMAE, Hand, Human, Tumor microenvironment, Liraglutide, ATM, IND, ASCO, Obesity, Patient, Cleavage, MUC, Annual general meeting, CSPC, CB1, Cervical cancer, Biotechnology, Therapy, Insulin resistance

Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024

Key Points: 
  • Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024
    NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2024.
  • We look forward to CSPC’s presentation of updated data at the ASCO 2024 Annual Meeting.
  • During the quarter, we also continued to advance CRB-913 for the treatment of obesity and expect to dose the first patient in Q1 2025.
  • Updated data from this study will be presented by CSPC as a poster at the ASCO 2024 Annual Meeting on June 1, 2024.

InventHelp Inventor Develops Improved Brassiere for Women (BEC-342)

Retrieved on: 
Montag, April 29, 2024
Rash, Suite, Sale, Pain, Multimedia, Perspiration, Candidiasis

This patent-pending invention provides an improved design for a bra.

Key Points: 
  • This patent-pending invention provides an improved design for a bra.
  • The invention features a unique design that is easy to wear and use so it is ideal for anyone with breasts.
  • The original design was submitted to the National sales office of InventHelp.
  • 22-BEC-342, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Starton Therapeutics Announces Enrollment Completion for STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma

Retrieved on: 
Donnerstag, April 25, 2024
Dexamethasone, FDA, Multiple myeloma, Safety, Pharmacokinetics, Bortezomib, Neutropenia, Science, CLL, Patient, Fatigue, Rash, Malignancy, Clinical trial, Therapy, Lenalidomide, Pharmaceutical industry

PARAMUS, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today the successful completion of enrollment for its STAR-LLD Phase 1b clinical trial in multiple myeloma.

Key Points: 
  • PARAMUS, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today the successful completion of enrollment for its STAR-LLD Phase 1b clinical trial in multiple myeloma.
  • “This milestone marks a significant step forward in our commitment to bringing more advanced therapies to patients.
  • We extend our gratitude to the participants, investigators, and clinical teams whose dedication and collaboration have made this achievement possible significantly ahead of our original timelines,” stated Pedro Lichtinger, Chairman and CEO of Starton Therapeutics.
  • Together, we are not just advancing science; we are transforming lives.”
    Starton previously disclosed preliminary trial findings regarding the safety and efficacy of STAR-LLD for multiple myeloma.

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Retrieved on: 
Dienstag, April 23, 2024
Neuro-Oncology (journal), First grade, FDA, Society, University, BRAF V600, Day One, Hospital, Acne, Safety, Food, Biopharmaceutical, Conference call, Nausea, Insurance, Conference, Research, Webcast, Viral, Speech, Fatigue, Human, Disease, BRAF, Vomiting, Patient, Medicine, Headache, Event, Rash, Constipation, Diagnosis, Head, Neoplasm, Upper respiratory tract infection, PRS, Xeroderma, Fever, Caregiver, Ageing, Pharmaceutical industry

BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.

Key Points: 
  • With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.
  • “We are very proud that our first approved medicine addresses this serious and life-threatening disease of childhood and adolescence.
  • BRAF is the most commonly altered gene in pLGG, with up to 75 percent of children having a BRAF alteration.
  • “This is a tremendous moment not only for Day One, but also for the broader pediatric brain tumor community.

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Retrieved on: 
Mittwoch, Mai 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mortality, FDA, Risk, ICS, Death, Weight loss, Growth, Gastrointestinal tract, Rash, TSLP, Formoterol, Biopharmaceutical, AstraZeneca, LABA, Inflammation, Salbutamol, Skin, Tezepelumab, Approval, EGPA, AMG, Allergy, Polyp (medicine), Bronchitis, Chronic obstructive pulmonary disease, Patient, Eosinophilic, Sinusitis, Rheumatology, Heart, Atmosphere, Fatigue, Immunology, Budesonide, Lung, Chronic pain, Asthma, COPD, Gastroenterology, Emphysema, Disease, Science, Conditional sentence, Dermatology, Pharmaceutical industry

In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.

Key Points: 
  • In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.
  • Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Retrieved on: 
Montag, April 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Other Health, Dermatitis, Itch, Pain, Shanda, Skin, Inflammation, Food, Swelling, Stinger, Rash, Body surface area, Nose, Agency, Atopic dermatitis, Folliculitis, Common, Therapy, PDUFA, Incidence, Patient, Psoriasis, Red, Headache, Irritation, Ageing, Pharmaceutical industry

The Prescription Drug User Fee Act ("PDUFA") action date assigned by the Agency is in Q4 2024.

Key Points: 
  • The Prescription Drug User Fee Act ("PDUFA") action date assigned by the Agency is in Q4 2024.
  • VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of AD.
  • On May 24, 2022, Dermavant announced the FDA approved VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

Cedars-Sinai Launches Virtual Healthcare for Children and Spanish Speakers

Retrieved on: 
Mittwoch, April 10, 2024
Software, General Health, Hispanic, Family, Telemedicine, Virtual Medicine, Consumer, Apps, Applications, Technology, Artificial Intelligence, Health Technology, Parenting, Children, Health, Pain, Language, AI, MD, Partnership, Cough, Parent, Depression, Obesity, Patient, Rash, Child, Anxiety, Connect, Nursing

Cedars-Sinai is expanding virtual healthcare for children and Spanish speakers in California through its mobile app Cedars-Sinai Connect , a fast-growing online option that allows patients to quickly access top healthcare professionals for acute, chronic and preventive care.

Key Points: 
  • Cedars-Sinai is expanding virtual healthcare for children and Spanish speakers in California through its mobile app Cedars-Sinai Connect , a fast-growing online option that allows patients to quickly access top healthcare professionals for acute, chronic and preventive care.
  • Parents of children 3 to 17 years old can now access Cedars-Sinai healthcare providers for urgent issues, including cough, cold, flu or rash.
  • Spanish-speaking healthcare providers are available for scheduled visits 7 a.m.-9 p.m. on weekdays and 8 a.m.-4 p.m. on weekends.
  • These patients also gain access to our broad network of specialists through referrals when appropriate.”
    The new care options for children and Spanish speakers build on Cedars-Sinai Connect’s initial success.